AzTrials
AzTrials

Ischemic StrokeESU-ACE-ENCT06728592

Emergency Stroke Unit for Acute Cerebrovascular Events: A Prospective, Single-arm Trial With a Historical Control Group

A study testing Portable Magnetic Resonance Imaging in people with Ischemic Stroke and Intracerebral Hemorrhage, run by Chinese University of Hong Kong at 1 site in Hong Kong.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

Background Reperfusion therapies, i.e., intravenous thrombolysis (IVT) and/or endovascular thrombectomy (EVT), are most effective treatments in the management of acute ischemic stroke (AIS) patients. Read more about this study

Who is it for?
Ages 18 to 100 years
Conditions the study is for
Ischemic Stroke, Intracerebral Hemorrhage, Stroke
What is being tested?
Portable Magnetic Resonance Imaging
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteHong Kong
Study dates
2 Dec 2024to 31 Dec 2028
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 100 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥18 years;
  • Diagnosed as ischemic stroke;
  • Eligible for IVT and/or EVT and can be treated within 6 hours of symptom onset (time of symptom onset is defined as the last known normal time);
  • Presenting to AED during working hours (8AM to 6PM, weekdays);
  • Written informed consent from patients or representatives, who understand Cantonese, to participate in this study.

Who cannot join

  • Patients with unstable vital signs who need urgent medical interventions/care;
  • Confirmed contraindications for IVT or EVT by initial assessment (e.g., unstable vital signs, history of severe head trauma within 3 months, known bleeding tendency), before starting brain imaging exams;
  • Claustrophobia or other conditions that are contraindicated for MRI;
  • Patients with pacemakers, brain stimulators or insulin pumps;
  • Patients with medical or other conditions that prevent cooperation with the procedures;
  • Pregnant or breastfeeding women;
  • Participation in other clinical trials within 3 months before screening.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Thomas Wai Hong LEUNG, MD contact

852-28902002

drtleung@cuhk.edu.hk

Xinyi LENG, PhD contact

852-28953968

xinyi_leng@cuhk.edu.hk

Hong Kong1 site, 1 recruiting
  • Chinese University of Hong Kong

    Hong Kong

    Thomas Wai Hong LEUNG, MD, 852-28902002, drtleung@cuhk.edu.hk

    Xinyi LENG, PhD, 852-28953968, xinyi_leng@cuhk.edu.hk

    Recruiting

Other trials in Hong Kong

About this study

Background Reperfusion therapies, i.e., intravenous thrombolysis (IVT) and/or endovascular thrombectomy (EVT), are most effective treatments in the management of acute ischemic stroke (AIS) patients. The benefits of reperfusion therapies, however, may be reduced by treatment delays due to tests and examinations and logistic issues. Emergency Stroke Unit (ESU), a new concept of stroke unit locating at the Accident and Emergency Department (AED), equipped with a mobile, low-field MR imaging (lfMRI) scanner for fast diagnosis of ischemic stroke, differentiation of intracranial hemorrhage and identification of large vessel occlusion (LVO), is being tested in Mainland China. It may shorten the door-to-needle time (DNT) for IVT and door-to-groin puncture time (DPT) for EVT, which may hance associate with improved functional outcomes of AIS patients.

This is a prospective, single-center, open-label, non-randomized, single-arm study aims to evaluate the safety and efficacy of the ESU workflow using lfMRI in shortening the DNT/DPT and improving functional outcomes in AIS patients, who are eligible for IVT and/or EVT and can be treated within 6 hours after onset, compared with standard practice in Hong Kong; to reveal the changes in the ischemic lesions over a few days after IVT/EVT in these patients, with serial follow-up lfMRI exams.

Read the detailed description

Background:

Reperfusion therapies, i.e., intravenous thrombolysis (IVT) and/or endovascular thrombectomy (EVT), are most effective treatments in the management of acute ischemic stroke (AIS) patients. The benefits of reperfusion therapies, however, may be reduced by treatment delays due to tests and examinations and logistic issues. Emergency Stroke Unit (ESU), a new concept of stroke unit locating at the Accident and Emergency Department (AED), equipped with a mobile, low-field MR imaging (lfMRI) scanner for fast diagnosis of ischemic stroke, differentiation of intracranial hemorrhage and identification of large vessel occlusion (LVO), is being tested in Mainland China. It may shorten the door-to-needle time (DNT) for IVT and door-to-groin puncture time (DPT) for EVT, which may hance associate with improved functional outcomes of AIS patients.

Objectives:

To evaluate the safety and efficacy of the ESU workflow using lfMRI in shortening the DNT/DPT and improving functional outcomes in AIS patients, who are eligible for IVT and/or EVT and can be treated within 6 hours after onset, compared with standard practice in Hong Kong; to reveal the changes in the ischemic lesions over a few days after IVT/EVT in these patients, with serial follow-up lfMRI exams.

Methods:

This is a prospective, single-center, open-label, non-randomized, single-arm trial with a historical control group (1:2). In the trial group, the investigators will recruit 60 adult AIS patients presenting during working hours, who are eligible for IVT and/or EVT therapies and can be treated within 6 hours of symptom onset; all workflow will be the same with standard care according to contemporary guidelines, except that patient triage procedures related to diagnosis of ischemic stroke, differentiation of intracranial hemorrhage and identification of LVO will be conducted at ESU using lfMRI. A historical control group of 120 patients managed by standard workflow (using CT brain for imaging assessment), in the 3 years before start of this study, will be drawn from our prospective IVT/EVT registry.

The investigators shall collect clinical data at baseline, 24 hours, 72 hours, 5 days, 7 days, discharge (or 14 days if earlier), and 90 days. Patients will also receive follow-up lfMRI exams at 24 hours, 72 hours, 5 days, 7 days, 14 days (or discharge). The primary outcome is DNT (min) for IVT. Main secondary outcomes include DPT (min) for EVT, proportions of patients receiving IVT and/or EVT therapies, door-to-recanalization time for EVT, mRS and NIHSS at discharge (or 14 days), mRS at 90 days, and costeffectiveness analysis. Main safety outcomes include symptomatic intracranial hemorrhage within 36 hours, before discharge (or 14 days) and within 90 days, and mortality, adverse events, severe adverse events within 90 days. Imaging outcomes include changes of infarct volume over time, and changes/emergence of hemorrhagic transformation.

Significance:

Findings from this project and subsequent efforts could help reshape and improve the efficiency of IVT/EVT patient triage at AED, which will ultimately benefit stroke patients and the stroke care system in Hong Kong and elsewhere.

Being tested
Portable Magnetic Resonance Imaging
Medical subject headings
Ischemic Stroke, Cerebral Hemorrhage, Stroke, Hemorrhagic Stroke, Brain Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Portable Magnetic Resonance ImagingDevice

    Also called Low-field Magnetic Resonance Imaging

    0.23T Low-field Magnetic Resonance Imaging

Study groups in NCT06728592
Study groupRoleWhat they receive
Acute ischemic stroke patients , eligible for IVT and/or EVTExperimentalAcute ischemic stroke patients who are eligible for IVT and/or EVT therapies and can be treated within 6 hours of symptom onset, will be triaged for intravenous thrombolysis (IVT) and/or endovascular thrombectomy (EVT) in Emergency Stroke Unit (ESU) based on lfMRI for diagnosis of ischemic stroke, differentiation of intracerebral hemorrhage (ICH) and identification of large vessel occlusion (LVO). Other screening and assessment procedures for IVT/EVT, and clinical management of the patients, are the same with standard practice as recommended by contemporary guidelines. In the historical control group, patients were triaged for IVT and/or EVT by standard practice, using plain CT and CTA for imaging triage.
Receives: Device: Portable Magnetic Resonance Imaging

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Door-to-Needle time(min) for intravenous thrombolysis

    Reduction in the Door-to-Needle time(min) for intravenous thrombolysis

    Measured: Day 0

Secondary outcomes (6)
  1. Door-to-Groin Puncture time (min) for endovascular thrombectomy (EVT)

    Reduction in the Door-to-Groin Puncture time (min) for endovascular thrombectomy

    Measured: Day 0

  2. Time from symptom onset to decision for IVT/EVT (min)

    Reduction in time from symptom onset to decision for IVT/EVT (min)

    Measured: Day 0

  3. Time from admission to decision for IVT/EVT (min)

    Reduction in time from admission to decision for IVT/EVT (min)

    Measured: Day 0

  4. Improvement in NIHSS score at 24 hours compared to baseline

    30% improvement in NIHSS score at 24 hours compared to baseline

    Measured: From Day 0, post treatment, to Day 1.

  5. modified Rankin Scale (mRS)

    mRS 0-1 at discharge (or 14±2 days), and at 90±7 days ; mRS 0-2 at discharge (or 14±2 days), and at 90±7 days ; mRS distribution at discharge (or 14±2 days), and at 90±7 days

    Measured: From Day 0 post treatment, up to 90 Days.

  6. Door-to-reperfusion time (min) in EVT

    Door-to-reperfusion time (min) in EVT

    Measured: Day 0

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Dec 2024
  2. Study start2 Dec 2024
  3. Primary completion31 Dec 2027 (estimated)
  4. Study completion31 Dec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06728592
Sponsor's protocol ID
Crec No. 2024.400T
Acronym
ESU-ACE-E
Status last verified
Sep 2026
First submitted
5 Dec 2024
Last updated
10 Sep 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in